相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
Marc De Hert et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices
A. J. Mitchell et al.
PSYCHOLOGICAL MEDICINE (2012)
A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
T. Scott Stroup et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of Psychosis
Debra L. Foley et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation
M. De Hert et al.
BRITISH JOURNAL OF PSYCHIATRY (2011)
Association of the metabolic syndrome with physical activity performance in patients with schizophrenia
D. Vancampfort et al.
DIABETES & METABOLISM (2011)
Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
M. De Hert et al.
EUROPEAN PSYCHIATRY (2011)
Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents
Lawrence Maayan et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2011)
Endogenic and Iatrogenic Diabetes Mellitus in Drug-naive Schizophrenia: The Role of Olanzapine and its Place in the Psychopharmacological Treatment Algorithm
Dan Cohen et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Life expectancy among persons with schizophrenia or bipolar affective disorder
Thomas Munk Laursen
SCHIZOPHRENIA RESEARCH (2011)
Cardiovascular risk in a first-episode psychosis sample: A 'critical period' for prevention?
Viyek H. Phutane et al.
SCHIZOPHRENIA RESEARCH (2011)
Twenty-five year mortality of a community cohort with schizophrenia
Steve Brown et al.
BRITISH JOURNAL OF PSYCHIATRY (2010)
Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics
Mehrul Hasnain et al.
CURRENT DIABETES REPORTS (2010)
MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study
Ruud van Winkel et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2010)
The Metabolic Syndrome and Cardiovascular Risk A Systematic Review and Meta-Analysis
Salvatore Mottillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naive Schizophrenia Patients
Jimmi Nielsen et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia
Davy Vancampfort et al.
PSYCHIATRY RESEARCH (2010)
Weight gain in antipsychotic-naive patients: a review and meta-analysis
I. Tarricone et al.
PSYCHOLOGICAL MEDICINE (2010)
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Christine Rummel-Kluge et al.
SCHIZOPHRENIA RESEARCH (2010)
Physical activity and fitness in adolescents at risk for psychosis within the Northern Finland 1986 Birth Cohort
J. Koivukangas et al.
SCHIZOPHRENIA RESEARCH (2010)
Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort
Julio Bobes et al.
SCHIZOPHRENIA RESEARCH (2010)
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)
M. De Hert et al.
EUROPEAN PSYCHIATRY (2009)
Metabolic Risk Factors in Drug-Naive Patients With First-Episode Psychosis
Swapna K. Verma et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders - A systematic critical reappraisal
Mario Alvarez-Jimenez et al.
CNS DRUGS (2008)
Body mass index (BMI) of drug-naive psychotic adolescents based on a population of adolescent psychiatric inpatients
Jaana Juutinen et al.
EUROPEAN PSYCHIATRY (2008)
Defining the metabolic syndrome in children and adolescents: Will the real definition please stand up?
Earl S. Ford et al.
JOURNAL OF PEDIATRICS (2008)
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder:: an open randomised clinical trial
Rene S. Kahn et al.
LANCET (2008)
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
Marc De Hert et al.
SCHIZOPHRENIA RESEARCH (2008)
Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects
Karen A. Graham et al.
SCHIZOPHRENIA RESEARCH (2008)
Mortality in schizophrenia and schizoaffective disorder: An Olmsted county, Minnesota cohort: 1950-2005
Rebecca M. Capasso et al.
SCHIZOPHRENIA RESEARCH (2008)
Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?
Sarojini Sengupta et al.
SCHIZOPHRENIA RESEARCH (2008)
A systematic review of mortality in schizophrenia - Is the differential mortality gap worsening over time?
Sukanta Saha et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
Balancing efficacy and safety in treatment with antipsychotics
Christoph U. Correll
CNS SPECTRUMS (2007)
Distress with medication side effects among persons with severe mental illness
Nancy H. Covell et al.
ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH (2007)
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison
Joseph P. McEvoy et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia
L. M. Spelman et al.
DIABETIC MEDICINE (2007)
Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE®
Marc De Hert et al.
SCHIZOPHRENIA RESEARCH (2006)
Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity
Luc F. Van Gaal
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2006)
Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients:: A randomized controlled trial
Mario Alvarez-Jimenez et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation
KGMM Alberti et al.
DIABETIC MEDICINE (2006)
Prevalence of diabetes and impaired fasting glucose in adults in the US population - National Health and Nutrition Examination Survey 1999-2002
Catherine C. Cowie et al.
DIABETES CARE (2006)
Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
SM Grundy et al.
CIRCULATION (2005)
Size of burden of schizophrenia and psychotic disorders
W Rössler et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Arterial stiffness and stroke in hypertension - Therapeutic implications for stroke prevention
S Laurent et al.
CNS DRUGS (2005)
Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients
B Arranz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2004)
Physical health monitoring of patients with schizophrenia
SR Marder et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Obesity as a risk factor for antipsychotic noncompliance
PJ Weiden et al.
SCHIZOPHRENIA RESEARCH (2004)
Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia
MCM Ryan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Nutritional assessment of patients with schizophrenia: A preliminary study
M Strassnig et al.
SCHIZOPHRENIA BULLETIN (2003)
Physical consequences of schizophrenia and its treatment - The metabolic syndrome
MCM Ryan et al.
LIFE SCIENCES (2002)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Causes of the excess mortality of schizophrenia
S Brown et al.
BRITISH JOURNAL OF PSYCHIATRY (2000)
Time trends in schizophrenia mortality in Stockholm County, Sweden:: cohort study
U Ösby et al.
BRITISH MEDICAL JOURNAL (2000)
分享论文
